Tag: SIRT

Lessons from randomised controlled trials utilising SIRT in liver cancer

A recent session at CIRSE 2018 sought to go beyond the headline findings from a number of recent randomised controlled trials (RCTs) in interventional...

Sirtex prefers US$1.4 billion CDH-CGP bid to Varian’s acquisition offer

Sirtex has announced entering into a binding scheme implementation deed with CDH Genetech (CDH) and China Grand Pharmaceuticals and Healthcare Holdings Limited (CGP). It...

Establishing the evidence base for SIRT in Interventional Oncology

Multidisciplinary oncology thought leaders discuss the personalisation of SIRT, new and recent evidence for the minimally invasive procedure over sorafenib in advanced HCC, the...

SIRT fails to extend survival in the SORAMIC study palliative cohort

  The SORAMIC study, presented at The International Liver Congress, shows that the addition of selective internal radiation therapy (SIRT) to sorafenib in patients with...

MIM software receives US FDA 510(k) clearance for post-treatment dosimetry of...

Dosimetry, within the context of selective internal radiation therapy (SIRT) using Y-90 microspheres, is typically understood to be the measurement and calculation of the...

Terumo launches QuiremSpheres microspheres in Europe

Terumo has announced that it has launched QuiremSpheres microspheres in Europe on 18 September. QuiremSpheres, the next generation of selective internal radiation therapy (SIRT) microspheres...

SIRveNIB abstract published by ASCO, to be presented on 4 June

SIRveNIB is an investigator-led Asia Pacific Primary Liver Cancer Study to be presented on 4 June 2017 at the American Society of Clinical Oncology...

REsect study shows SIRT makes metastatic colorectal cancer patients more likely...

Metastatic colorectal cancer patients treated first-line with SIR-spheres Y-90 resin microspheres more likely to become candidates for potentially curative liver surgery, the REsect study...

New data show SIRT does not prolong overall survival in metastatic...

The FOXFIRE, SIRFLOX and FOXFIRE Global randomised studies evaluated the efficacy of combining first-line chemotherapy for metastatic colorectal cancer with selective internal radiotherapy (SIRT)...

SIRT significantly better tolerated than sorafenib, but does not increase overall...

The 459-patient randomised controlled SARAH study shows that local treatments of advanced or inoperable hepatocellular carcinoma with selective internal radiation therapy (SIRT) did not...

New NCCN guidelines recommend SIRT for the treatment of metastatic colorectal...

Sirtex has announced that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network...

SIRT access “under threat” from commissioning through evaluation process

Selective internal radiation therapy (SIRT) has been available since December 2013 to a defined group of patients with liver metastases in England on the...

BTG and Mirada Medical announce CE mark certification for Simplicit90Y dosimetry...

BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy...

New ESMO biliary cancer guidelines indicate radioembolization as an option for...

New European Society of Medical Oncology (ESMO) biliary cancer guidelines indicate yttrium-90 (Y-90) therapy as an option for post-chemotherapy treatment of intrahepatic cholangiocarcinoma. Sirtex has announced...